BioSpace News Archive

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences. Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. The ma

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2020 RBC Capital Markets Global Healthcare Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced today that an abstract on the Phase 1/2 clinical trial of seclidemstat in Ewing sarcoma has been accepted as a poster at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held Friday, May 29, 2020 through Sunday, May 31, 2020. The poster, titled, “A phase I/II cl

KB105 was well tolerated with no adverse events or immune response following redosing Clearly detectable TGM-1 expression in all treated areas following initial and repeat administration. KB105-expressed TGM1 was correctly localized in the epidermis, co-localizing with loricrin, and was functionally active Phenotypic evaluation of KB105 treated areas showed reduced reversion to ichthyotic scaling phenotype Amy Paller, M.D., Professor and Chair of Dermatology at Northwestern University

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-009-05 clinical study in which Cellworks Singula™ correctly predicted 94.2% of Pancreatic Cancer (PDAC) responders and non-responders with 100% sensitivity and 90.3% specificity, compared to a 40.4% physician prescribed treatment response rate.

Smith+Nephew, the global medical technology business, announces its newly launched OR3O Dual Mobility System for total hip arthroplasty has received encouraging results from early surgeon experience.

First Patient Dosed with Optimized One-Hour Dosing Schedule for Investigational Agent Alvocidib After Azacitidine

Detroit-based Redcliffe Medical has launched a breakthrough transparent face mask with state of the art N99+ HEPA-Carbon filtration, powered by optional UV self-sterilization and active ventilation.

First phase will see drive-thru sites open across five states this week; more than 900 additional sites will open over next two weeks

Seattle Genetics Announces ADCETRIS ® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma - Approval Based on Positive ECHELON-2 Phase 3 Trial Results Demonstrating Superior Progression-Free Survival and Overall Survival with ADCETRIS plus CHP Chemotherapy - BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced